PB0121 - Relationship of Thrombo-Inflammatory Biomarkers with Oxidative Stress Level in Non-Small Cell Lung Cancer Patients

Sunday, June 25, 2023

18:30 – 19:30 ET

Room: Exhibition

Co-Author(s)

Srdjan S. Nikolovski, MD

Sr Staff Scientist
Loyola University Chicago
Lyons, Illinois, United States

Co-Author(s)

Mark Jaradeh

Medical Student
Department of Molecular Pharmacology & Neuroscience, Loyola University Medical Center, 2160 S. 1st Avenue, Maywood, IL 60153, USA.
Brookfield, Illinois, United States
JW

Jeanine Walenga

Professor
Loyola University Chicago
Chicago, Illinois, United States

Presenting Author(s)

Fakiha Siddiqui, PhD Candidate

PhD Candidate
Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
Maywood, Illinois, United States

Co-Author(s)

DH

Debra Hoppensteadt

Professor
Loyola University Chicago
Chicago, Illinois, United States
Bulent Kantarcioglu, MD

MD
Loyola University Chicago
Chicago, Illinois, United States
JF

Jawed Fareed, n/a

Professor
Loyola University Medical Center
MAYWOOD, Illinois, United States
WV

Wiicki Vigneswaran

M.D.
Loyola University Medical Center
Maywood, Illinois, United States

Background: Lung cancer is one of the most common and the most catastrophic malignancy globally. Thromboembolic events have been associated with increased mortality and adverse outcomes. This study compared levels of thrombo-inflammatory and oxidative stress biomarkers in non-small cell lung cancer (NSCLC) patients and healthy controls.

Aims: To compare thrombo-inflammatory and oxidative stress biomarker levels in NSCLC patients to those in normal human population (NHP) and to investigate the association between thrombo-inflammatory and oxidative stress-related biomarker levels.

Methods: After obtaining written informed consent, pre-operative plasma samples of 49 patients with histologically confirmed NSCLC were obtained in accordance with an IRB-approved protocol. Control samples were obtained from 34 healthy individuals. Plasma biomarkers related to thrombo-inflammation and oxidative stress were determined by enzyme-linked immunosorbent assay. Applicable statistical methods were used to analyze the data.

Results: Comparison of plasma biomarker levels revealed tissue plasminogen activator (tPA) to be significantly higher in NSCLC patients (p=0.011) and urokinase-type plasminogen activator (uPA) levels to be significantly higher in NHP (p=0.009). NSCLC patient plasma also demonstrated significantly higher levels of nitrotyrosine and myeloperoxidase (MPO) (p=0.002 and p=0.012, respectively). Among NSCLC patients, tPA and uPA plasma levels demonstrated significant correlation (r=0.328, p=0.005). Correlations were also observed between thrombin activatable fibrinolysis inhibitor (TAFI) and factor IX (FIX) levels (r=0.481, p< 0.001) and endogenous glycosaminoglycans and MPO levels (r=0.386, p=0.006). Linear regression analysis found TAFI to be an independent predictor of FIX levels (p=0.006, OR 0.454). The composite data is represented in Table 1 and Figure 1.

Conclusion(s): We found levels of tPA, nitrotyrosine, and MPO to be elevated and levels of NPH and uPA to be lower in NSCLC patients relative to NPH. Additionally, we found positive correlations between tPA and uPA and TAFI and FIX plasma levels in NSCLC patients. These findings also underscore the fibrinolytic deficit in NSCLC.